Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection
- Conditions
- COVID19ACE InhibitorsAntihistamine AllergyAmantadineARBInfluenza Vaccination
- Interventions
- Registration Number
- NCT04367883
- Lead Sponsor
- Consorci Sanitari de Terrassa
- Brief Summary
Some authors have proposed the use of the flu vaccine to reduce the severity of COVID-19 cases, while some have proposed the use of ACE Inhibitors (ACEI) or Angiotensin Receptor blockers (ARB), since this virus shares hemagglutinin as a transmission mechanism and acts on the ACE2 enzyme during infection.
Other authors described how none of the elderly patients receiving antihistamines and azythromycin in two nursing homes in Toledo -Spain- during the first wave died or needed hospital admission, even considering that 100% of residents had a positive serological test after that wave. Other authors have described a positive evolution in patients receiving amantadine for their Parkinson's disease.
The aim is to evaluate whether the admitted patients who are previously vaccinated or those who were already receiving these treatments showed a better evolution.
- Detailed Description
The number COVID cases would be related to hospital admissions. Among hospital admissions, the number of previous treatments, the length of admission, the need or not of the Intensive Care Unit (ICU) and their final status (survivors or non survivors) would be studied.
If patients that previously received the influenza vaccine or treated with ACEI, ARB, antihistamines or amantadine showed a better evolution, it would be proposed to extend vaccination and the inclusion of ACE inhibitors, ARB, antihistamines or amantadine in the treatment of infection.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 3000
- Hospital Admissions at the Hospital of Terrassa from March 1, 2020 for any cause.
- None.
- For comparison of percentage of Influenza vaccination, ACEI and ARB vs general population, patients from outside the reference area of the Terrassa Health Consortium would be excluded.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Hospital admissions, postcovid syndrome and thrombosis among COVID cases in CST population Antihistamine Observation of patient characteristics of hospital incomes in Hospital of Terrassa from March 1, 2020. No intervention is performed. Hospital admissions, postcovid syndrome and thrombosis among COVID cases in CST population Amantadine Observation of patient characteristics of hospital incomes in Hospital of Terrassa from March 1, 2020. No intervention is performed. Hospital admissions, postcovid syndrome and thrombosis among COVID cases in CST population ACEI Observation of patient characteristics of hospital incomes in Hospital of Terrassa from March 1, 2020. No intervention is performed. Hospital admissions, postcovid syndrome and thrombosis among COVID cases in CST population ARB Observation of patient characteristics of hospital incomes in Hospital of Terrassa from March 1, 2020. No intervention is performed. Hospital admissions, postcovid syndrome and thrombosis among COVID cases in CST population Influenza vaccine and COVID Observation of patient characteristics of hospital incomes in Hospital of Terrassa from March 1, 2020. No intervention is performed. Evolution of COVID cases in patients receiving antihistamines Antihistamine COVID cases, hospital admissions, postcovid syndrome, thrombosis and deaths related to COVID from march 1, 2020 in patients of the participating institutions receiving chronic treatment with antihistamines. No intervention is performed. Evolution of COVID cases in patients receiving amantadine. Amantadine COVID cases, hospital admissions, postcovid syndrome, thrombosis and deaths related to COVID from march 1, 2020 in patients of the participating institutions receiving chronic treatment with amantadine. No intervention is performed.
- Primary Outcome Measures
Name Time Method hospital output from March 1, 2020. exitus vs hospital output
- Secondary Outcome Measures
Name Time Method hospital stay From March 1, 2020. length of the hospital stay
Trial Locations
- Locations (1)
Hospital de Terrassa
🇪🇸Terrassa, Barcelona, Spain